Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 20/20 | 0.59 |
| ▸ | FLT3 | P36888 | 4/20 | 0.57 |
| ▸ | PDGFRA | P16234 | 12/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.56 |
| ▸ | KDR | P35968 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.56 |
| ▸ | KIT | P10721 | 1/20 | 0.56 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21851748 | 0.92 | CSF1R (0.59) | CSF1RFLT3PDGFRAPDGFRBKDR | |
| SCHEMBL16046296 | 0.91 | CSF1R (0.68) | CSF1RFLT3PDGFRAPDGFRBKDR | |
| SCHEMBL21824045 | 0.91 | CSF1R (0.57) | CSF1RFLT3PDGFRAPDGFRBKDR | |
| SCHEMBL16046080 | 0.89 | CSF1R (0.59) | CSF1RFLT3PDGFRAPDGFRBKDR | |
| SCHEMBL16046362 | 0.88 | CSF1R (0.67) | CSF1RFLT3PDGFRAPDGFRBKDR | |
| SCHEMBL16046826 | 0.88 | CSF1R (0.61) | CSF1RFLT3PDGFRAPDGFRBKDR | |
| SCHEMBL16046825 | 0.88 | CSF1R (0.61) | CSF1RFLT3PDGFRAPDGFRBKDR | |
| SCHEMBL16048363 | 0.86 | CSF1R (0.59) | CSF1RFLT3PDGFRAPDGFRBKDR | |
| SCHEMBL16046249 | 0.86 | CSF1R (0.70) | CSF1RFLT3PDGFRAPDGFRBKDR | |
| SCHEMBL16046266 | 0.85 | CSF1R (0.69) | CSF1RFLT3PDGFRAPDGFRBKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107311981-B | 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activity | 德西费拉制药有限责任公司 | 2020-05-29 | — | — | CN | disclosed |
| EP-2968286-B1 | 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS LLC (US) | 2017-09-13 | — | — | EP | disclosed |
| EP-2968286-A2 | 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | Deciphera Pharmaceuticals, LLC (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9181223-B2 | 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2015-11-10 | — | — | US | disclosed |
| WO-2014145025-A2 | 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275085-A1 | 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275085-A1 | 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | CSF1R, KIT, CSF3R | CSF1R 1/4885FLT3 4/4885PDGFRA 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.